Home207940 • KRX
add
Samsung Biologics Co Ltd
Nakaraang pagsara
₩1,133,000.00
Sakop ng araw
₩1,110,000.00 - ₩1,133,000.00
Sakop ng taon
₩907,000.00 - ₩1,209,000.00
Market cap
79.50T KRW
Average na Volume
76.36K
P/E ratio
61.83
Dividend yield
-
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (KRW) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 1.29T | 11.50% |
Gastos sa pagpapatakbo | 239.48B | 8.55% |
Net na kita | 324.39B | 2.01% |
Net profit margin | 25.15 | -8.51% |
Kita sa bawat share | 4.56K | 2.01% |
EBITDA | 653.80B | 12.23% |
Aktuwal na % ng binabayarang buwis | 20.67% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (KRW) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 1.64T | 4.85% |
Kabuuang asset | 17.77T | 8.75% |
Kabuuang sagutin | 6.17T | 2.60% |
Kabuuang equity | 11.60T | — |
Natitirang share | 71.17M | — |
Presyo para makapag-book | 6.95 | — |
Return on assets | 6.75% | — |
Return on capital | 9.25% | — |
Cash Flow
Net change in cash
| (KRW) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 324.39B | 2.01% |
Cash mula sa mga operasyon | 523.38B | 118.57% |
Cash mula sa pag-invest | -540.29B | -70.43% |
Cash mula sa financing | -2.62B | 91.92% |
Net change in cash | -42.58B | 50.81% |
Malayang cash flow | 251.99B | 144.79% |
Tungkol
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
CEO
Itinatag
2011
Website
Mga Empleyado
5,047
